Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 127 for epilepsy

Edit search filters
  1. IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

    Rochester, MN

  2. Study Of Cenobamate In Pediatric Subjects 2-17 Years Of Age With Partial-onset (Focal) Seizures

    Rochester, MN

  3. A Study Assess The Long-Term Safety Of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution In Children And Young Adults With Dravet Syndrome

    Rochester, MN

  4. Study Evaluating The Safety And Efficacy Of Fenfluramine Hydrochloride Oral Solution (ZX008)as Adjunctive Therapy In Children With Intractable Epilepsy With Myoclonic-Atonic Seizures

    Rochester, MN

  5. A Study To Assess Medtronic Deep Brain Stimulation (DBS) Therapy For Epilepsy Post-Approval (EPAS)

    Rochester, MN

  6. Stiripentol In Dravet Syndrome

    Rochester, MN

  7. A Study To Investigate LP352 In Children And Adults With Developmental And Epileptic Encephalopathy (DEE)

    Rochester, MN

  8. A Study Using SAGE-547 For Super Resistant Status Epilepticus

    Rochester, MN

  9. A Study To Assess The Long-Term Safety And Tolerability Of TAK-935 (OV935) As Adjunctive Therapy In Patients With Rare Epilepsy

    Rochester, MN

  10. Development of a Practical, Minimally Invasive Seizure Gauge

    Rochester, MN

.

Mayo Clinic Footer